Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBT (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed EBT for 4 consecutive years, with -$28.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 62.41% to -$28.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$183.7 million through Dec 2025, up 36.02% year-over-year, with the annual reading at -$183.7 million for FY2025, 36.02% up from the prior year.
  • EBT hit -$28.1 million in Q4 2025 for Axsome Therapeutics, up from -$47.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$8.6 million in Q1 2023 to a low of -$99.0 million in Q4 2023.
  • Historically, EBT has averaged -$56.0 million across 4 years, with a median of -$60.3 million in 2022.
  • Biggest five-year swings in EBT: skyrocketed 78.2% in 2023 and later tumbled 691.35% in 2024.
  • Year by year, EBT stood at -$61.2 million in 2022, then tumbled by 61.62% to -$99.0 million in 2023, then increased by 24.4% to -$74.8 million in 2024, then skyrocketed by 62.41% to -$28.1 million in 2025.
  • Business Quant data shows EBT for AXSM at -$28.1 million in Q4 2025, -$47.2 million in Q3 2025, and -$48.9 million in Q2 2025.